MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
SELLAS Life Sciences Group ROE Ratio 2011-2026 | SLS
Annual ROE Ratio SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.9 | -326.27 | 468.15 | -851.39 | -101.73 | -0.06 | -316.63 | -527.55 | -1147.54 | -82.18 | -472.89 | -98.78 | -1302.72 | -125.99 | -113.58 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 468.15 | -1302.72 | -335.8 |
Quarterly ROE Ratio SELLAS Life Sciences Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -105.79 | -135.64 | -366.83 | -399.95 | -157.8 | 129.08 | 202.98 | -24.65 | -80.39 | -378.28 | -239.9 | -515.9 | -542.52 | -513.41 | -483.06 | -48.79 | -64.79 | -54.16 | -56.18 | -46.64 | -115.6 | -168.57 | -204.18 | -194.86 | -200.39 | -136.96 | -201.1 | -273.54 | -488.75 | -698.44 | -868.52 | -723.14 | -747.32 | -556.28 | -251.82 | -62.93 | -196.32 | -305.54 | -440.24 | -327.26 | -343.92 | -227.18 | -165.1 | -98.9 | -192.61 | -293.68 | -148.31 | -400.08 | -377.27 | -324.49 | -472.47 | -230.22 | -213.47 | -202.67 | -183.37 | -129.25 | -54.14 | -37.12 | -37.98 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 202.98 | -868.52 | -257.23 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
-9.05 | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Milestone Pharmaceuticals
MIST
|
-150.97 | $ 1.36 | -20.0 % | $ 45.5 M |  Canada |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Inventiva S.A.
IVA
|
-30.23 | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Tiziana Life Sciences PLC
TLSA
|
-41.89 | $ 1.21 | -3.97 % | $ 71.5 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
-799.78 | $ 2.28 | -0.44 % | $ 1.03 M |  Israel |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Assembly Biosciences
ASMB
|
-2.96 | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.37 | -4.2 % | $ 350 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
10.1 | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
723.39 | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |